Chinese investors back Refuge Bio’s $25M B round as it steers gene engineering tech to an IND
A group of Chinese investors led by 3SBio and Sequoia China are bankrolling the next leg of development at Refuge Biotechnologies, a Bay Area biotech that’s been using CRISPR technology to control gene expression.
The syndicate is providing $25 million in a Series B as Refuge fine tunes a technology initially developed in the lab of Stanley Qi at Stanford. Qi mutated the Cas9 protein so it couldn’t do the cutting used in gene editing. That way it can be used to deliver a transcriptional activator or repressor to turn a gene off or on.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
